American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Horwitz
    Horwitz
  6. Abdel-Wahab
    Abdel-Wahab
  7. Palomba
    Palomba
  8. O'Reilly
    O'Reilly
  9. Noy
    Noy
  10. Papadopoulos
    Papadopoulos

Groups

  1. Hematologic Malignancies, Division of (3614)
  2. Department of Medicine (3585)
  3. Center for Hematologic Malignancies (3274)
  4. Adult Leukemia (1279)
  5. GSK Faculty (1153)
  6. Bone Marrow Transplant (902)
  7. Lymphoma (893)
  8. Executive Committee, Center for Hematologic Malignancies (764)
  9. Sloan Kettering Institute Faculty (682)
  10. Survivorship Research (656)
Search Within
  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (2778)
  2. Journal Article (746)
  3. Research Letter (30)
  4. Review (30)
  5. Editorial (21)
  6. Guidelines (6)
  7. Correspondence (3)
Groups
  1. Hematologic Malignancies, Division of (3614)
  2. Department of Medicine (3585)
  3. Center for Hematologic Malignancies (3274)
  4. Adult Leukemia (1279)
  5. GSK Faculty (1153)
  6. Bone Marrow Transplant (902)

More Groups

People
  1. Sergio Giralt (334)
  2. Andrew Zelenetz (326)
  3. Ross Levine (308)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (289)
  6. Steven Horwitz (258)

More People

Years
  1. 2025 (19)
  2. 2024 (131)
  3. 2023 (341)
  4. 2022 (277)
  5. 2021 (236)
  6. 2020 (209)

More Years

Publications
  1. Blood (3350)
  2. Blood Advances (223)
  3. Hematology-American Society of Hematology Education Program (41)

Results (3614)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pelabresib in combination with ruxolitinib for Janus Kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study
    Meeting Abstract

    Rampal, R. K.; Grosicki, S.; Chraniuk, D.; Abruzzese, E.; Bose, P.; Gerds, A. T.; Vannucchi, A. M.; Palandri, F.; Lee, S. E.; Gupta, V.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma
    Meeting Abstract

    Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: A prospective BMT-CTN study 1704
    Meeting Abstract

    Artz, A.; Logan, B. R.; Saber, W.; Geller, N.; Bellach, A.; Kou, J.; Wood, W.; McCarty, J. M.; Knight, T. G.; Runaas, L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Improved overall survival with axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma among the elderly: A subgroup analysis of ZUMA-7
    Meeting Abstract

    Kersten, M. J.; Farooq, U.; Rapoport, A. P.; Locke, F. L.; Leslie, L. A.; Ghobadi, A.; Miklos, D. B.; Jacobson, C. A.; Munoz, J. L.; Johnston, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3
    Meeting Abstract

    Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K. K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N. S.; Costa, L.; Vij, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Molecular taxonomy of myelodysplastic syndromes and its clinical implications
    Meeting Abstract

    Bernard, E.; Hasserjian, R.; Greenberg, P. L.; Ossa, J. E. A.; Creignou, M.; Nannya, Y.; Tuechler, H.; Medina-Martínez, J. S.; Levine, M. F.; Jädersten, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of obecabtagene autoleucel (obe-cel) in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia ([R/R B-ALL]; Pooled analysis from ALLCAR19 and FELIX phase Ib studies) or other B-cell malignancies (ALLCAR19 extension study)
    Meeting Abstract

    Roddie, C.; Tholouli, E.; Shaughnessy, P.; Jabbour, E.; Logan, A. C.; Hodby, K.; Mountjoy, L.; Bloor, A. J. C.; Irvine, D.; Linch, D. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in richter transformation: Updated efficacy and safety results with 18-month median survival follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term follow up for SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Advani, A. S.; Moseley, A. B.; O'Dwyer, K. M.; Wood, B. L.; Park, J. H.; Wieduwilt, M. J.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C)
    Meeting Abstract

    Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2023)

    Fulltext@MSK | Save